CCR4 Inhibitors
1 drugsAbout CCR4
CCR4 (C-C chemokine receptor type 4) is a receptor on immune cells that binds chemokines, triggering intracellular events affecting cell behavior and movement. It directs immune cell trafficking, particularly T cell migration to specific tissues, influencing immune responses.
CCR4 is a drug target due to its role in immune cell migration, but there is currently no genetic evidence available to support its role in disease. Modulation of CCR4 remains a potential therapeutic strategy despite the lack of genetic validation.
POTELIGEO, a biologic drug, is the only FDA-approved drug targeting CCR4, indicated for two conditions and developed by KYOWA KIRIN. This single drug highlights the potential, yet limited, therapeutic focus on CCR4.
Strategic Insights
ℹ️ How we calculate- White space opportunity in T-Cell Leukemia/Lymphoma, Adult with only 1 trials.
- phase2 represents biological uncertainty with 0% completion.
Top Drugs
KYOWA KIRIN is the only company with an approved drug targeting CCR4.
Low competition suggests potential for market entry, but also indicates higher risk due to limited validation.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets CCR4, using biologic (other) modality.
The absence of small molecule or antibody drugs represents a whitespace opportunity for novel CCR4-targeting modalities.
Clinical Trials 36 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 21 | 16 | 2 | 3 | 89% |
| Phase 2 | 9 | 1 | 0 | 8 | 100% |
| Phase 3 | 3 | 3 | 0 | 0 | 100% |
| Phase 4 | 3 | 1 | 1 | 1 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2018 - 2018)
POTELIGEO was first approved in 2018 and remains the only approved drug.
The lack of recent approvals suggests a potentially saturated market or challenges in developing new CCR4-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 25 clinical trials targeting CCR4.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities